Pharma giant AstraZeneca (NYSE:AZN) suffered two consecutive pipeline setbacks. The company recently announced that the development of its ovarian cancer candidate olaparib will be discontinued. Additionally, a phase III study of TC-5215 for major depressive disorder (MDD) did not meet its primary endpoint. AstraZeneca decided to stop the development process of olaparib as maintenance treatment [...]